Search Results - "Muskiet, Marcel H.A."

Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment by Tonneijck, Lennart, Muskiet, Marcel H A, Smits, Mark M, van Bommel, Erik J, Heerspink, Hiddo J L, van Raalte, Daniël H, Joles, Jaap A

“…An absolute, supraphysiologic elevation in GFR is observed early in the natural history in 10%-67% and 6%-73% of patients with type 1 and type 2 diabetes,…”
Get full text

SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome by van Bommel, Erik J M, Muskiet, Marcel H A, Tonneijck, Lennart, Kramer, Mark H H, Nieuwdorp, Max, van Raalte, Daniel H

“…Diabetic kidney disease not only has become the leading cause for ESRD worldwide but also, highly contributes to increased cardiovascular morbidity and…”
Get full text

SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes Management by van Baar, Michaël J B, van Ruiten, Charlotte C, Muskiet, Marcel H A, van Bloemendaal, Liselotte, IJzerman, Richard G, van Raalte, Daniël H

“…The progressive nature of type 2 diabetes (T2D) requires practitioners to periodically evaluate patients and intensify glucose-lowering treatment once glycemic…”
Get full text

The gut–renal axis: do incretin-based agents confer renoprotection in diabetes? by Muskiet, Marcel H. A., Smits, Mark M., Morsink, Linde M., Diamant, Michaela

“…Key Points Incretin-based therapies—glucagon-like peptide 1 receptor (GLP-1R) agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors—improve glycaemic control…”
Get full text

Renal sinus fat and renal hemodynamics: a cross-sectional analysis by Spit, Karlinde A., Muskiet, Marcel H. A., Tonneijck, Lennart, Smits, Mark M., Kramer, Mark H. H., Joles, Jaap A., de Boer, Anneloes, van Raalte, Daniel H.

“…Objectives Increased renal sinus fat (RSF) is associated with hypertension and chronic kidney disease, but underlying mechanisms are incompletely understood…”
Get full text

Effects of dapagliflozin and gliclazide on the cardiorenal axis in people with type 2 diabetes by van Bommel, Erik J.M., Smits, Mark M., Ruiter, Danique, Muskiet, Marcel H.A., Kramer, Mark H.H., Nieuwdorp, Max, Touw, Daan J., Heerspink, Hiddo J.L., Joles, Jaap A., van Raalte, Daniël H.

“…OBJECTIVES:There is a bidirectional relationship between cardiovascular and renal disease. The drug-class of SGLT2 inhibitors improves outcomes at both ends of…”
Get full text

A Randomized Trial of Intensive versus Standard Blood-Pressure Control by Pfeffer, Marc A, Vipler, Benjamin, Magee, Charles, Douglas, Kevin, Muskiet, Marcel H.A, Tonneijck, Lennart, Smits, Mark M, McCormick, Brendan B, Hiremath, Swapnil, Ruzicka, Marcel, Dai, Hailong, Guang, Xuefeng, Todd, Oliver, Clegg, Andrew, Pierard, Luc A, Bangalore, Sripal, Rimoldi, Stefano F, Messerli, Franz H, Wright, Jackson T, Whelton, Paul K, Reboussin, David M, Rodgers, Anthony, Perkovic, Vlado

“…To the Editor: Wright et al. (Nov. 26 issue) 1 report on the Systolic Blood Pressure Intervention Trial (SPRINT). By focusing on blood-pressure levels, rather…”
Get full text

SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes by van Bommel, Erik J M, Geurts, Frank, Muskiet, Marcel H A, Post, Adrian, Bakker, Stephan J L, Danser, A H Jan, Touw, Daan J, van Berkel, Miranda, Kramer, Mark H H, Nieuwdorp, Max, Ferrannini, Ele, Joles, Jaap A, Hoorn, Ewout J, van Raalte, Daniël H

“…Sodium-glucose transporter (SGLT)2 inhibitors increase plasma magnesium and plasma phosphate and may cause ketoacidosis, but the contribution of improved…”
Get more information

Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance by Emanuel, Anna L, Meijer, Rick I, Muskiet, Marcel H.A, van Raalte, Daniël H, Eringa, Etto C, Serné, Erik H

“…After food ingestion, macronutrients are transported to and stored in the skeletal muscle and adipose tissue. They can be subsequently used as an energy source…”
Get full text

GLP-1–Based Therapies Have No Microvascular Effects in Type 2 Diabetes Mellitus: An Acute and 12-Week Randomized, Double-Blind, Placebo-Controlled Trial by Smits, Mark M, Tonneijck, Lennart, Muskiet, Marcel H.A, Hoekstra, Trynke, Kramer, Mark H.H, Diamant, Michaela, Serné, Erik H, van Raalte, Daniël H

“…OBJECTIVE—To assess the effects of glucagon-like peptide (GLP)-1–based therapies (ie, GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) on…”
Get full text

Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus Patients by Tonneijck, Lennart, Muskiet, Marcel H.A, Twisk, Jos W, Kramer, Mark H.H, Danser, A.H Jan, Joles, Jaap A, Smits, Mark M, van Raalte, Daniël H

“…The prolonged treatment effects of a short-acting GLP-1RA (glucagon-like peptide-1 receptor agonist), such as lixisenatide, on fasting and postprandial…”
Get full text

Liraglutide and Renal Outcomes in Type 2 Diabetes by Tonneijck, Lennart, van Raalte, Daniël H, Muskiet, Marcel H.A, Gulli, Giovanni, Imprialos, Konstantinos P, Stavropoulos, Konstantinos, Doumas, Michael, Thornton, Simon N, Regnault, Véronique, Lacolley, Patrick, Mann, Johannes F.E, Ørsted, David D, Buse, John B, de Boer, Ian H

“…To the Editor: In reporting the results of the secondary analysis of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome…”
Get full text

GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men by Smits, Mark M, Muskiet, Marcel H.A, Tonneijck, Lennart, Kramer, Mark H.H, Diamant, Michaela, van Raalte, Daniël H, Serné, Erik H

“…OBJECTIVE—The insulinotropic gut–derived hormone glucagon-like peptide-1 (GLP-1) increases capillary perfusion via a nitric oxide–dependent mechanism in…”
Get full text

The effects of GLP-1 based therapies on postprandial haemodynamics: two randomised, placebo-controlled trials in overweight type 2 diabetes patients by Smits, Mark M, Tonneijck, Lennart, H.A. Muskiet, Marcel, Hoekstra, Trynke, H.H. Kramer, Mark, Diamant, Michaela, van Raalte, Daniël H

“…Graphical abstract…”
Get full text

Letter by Muskiet et al Regarding Article, “Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial” by Muskiet, Marcel H.A, Tonneijck, Lennart, van Raalte, Daniël H

Get full text

Incretin-based drugs and renoprotection-is hyperfiltration key? by Tonneijck, Lennart, Smits, Mark M, van Raalte, Daniël H, Muskiet, Marcel H A

Get more information

Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase by Smits, Mark M, Muskiet, Marcel H.A, Tushuizen, Maarten E, Kwa, Kelly A.A, Karemaker, John M, van Raalte, Daniël H, Diamant, Michaela

“…Highlights • Postprandial hypotension occurs in 25% of uncomplicated, early T2DM. • A reduction in peripheral vascular resistance is implicated. • Insulin…”
Get full text

Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial by Muskiet, Marcel H A, Tonneijck, Lennart, Huang, Yao, Liu, Minzhi, Saremi, Aramesh, Heerspink, Hiddo J L, van Raalte, Daniël H

“…The results of the ELIXA trial demonstrated the cardiovascular safety of lixisenatide, a short-acting glucagon-like peptide-1 receptor agonist, in patients…”
Get full text

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial by van Bommel, Erik J M, Muskiet, Marcel H A, van Baar, Michaël J B, Tonneijck, Lennart, Smits, Mark M, Emanuel, Anna L, Bozovic, Andrea, Danser, A H Jan, Geurts, Frank, Hoorn, Ewout J, Touw, Daan J, Larsen, Emil L, Poulsen, Henrik E, Kramer, Mark H H, Nieuwdorp, Max, Joles, Jaap A, van Raalte, Daniël H

“…Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve hard renal outcomes in type 2 diabetes. This is possibly explained by the fact that SGLT2i normalize…”
Get more information

New pharmacological strategies for protecting kidney function in type 2 diabetes by Muskiet, Marcel H A, Wheeler, David C, Heerspink, Hiddo J L

“…Type 2 diabetes is the leading cause of impaired kidney function, albuminuria, and renal replacement therapy globally, thus placing a large burden on…”
Get full text